Occam’s Board Practice Continues to Flourish
Occam Global placed Josh Ofman, MD, as Chairman of the Board of EveryONE Medicines in July 2024. The company was founded with seed financing from Khosla Ventures, GV, and Third Rock Ventures to develop treatments tailored to individual patients with ultra-orphan diseases.
Ofman is the President of GRAIL, a publicly-traded Illumina spinout backed by ARCH Venture Partners, Bezos Expeditions, Bill Gates, and Sutter Hill Ventures. He spent more than 15 years at Amgen, where he most recently held the role of Senior Vice President, Global Value, Access, and Policy.
Josh holds a BA in history and philosophy of science from the University of California, Berkeley, and an MD from theUniversity of California, Irvine, School of Medicine.
Occam Global is a biotech executive search, recruiting, and leadership advisory firm with specialties across technological fields, including Biotech, TechBio, AI-ML, Cell/Gene Therapy, Diagnostics/Genomics, Medical Devices, Research Tools, Digital Health, Alternative Energy, AgTech, EdTech, Robotics as well as adjacencies within Venture Capital and Private Equity. Occam helps build biotech executive leadership teams that meet the demands of the rapidly developing, competitive, and challenging industries it serves. Occam Global recruits leading C-Suite executives and board members for the most exciting and innovative clients across the world with a specific focus on the UK, Continental Europe, the US, and Asia.